[Market Focus] GC Wellbeing Rises 3.58% on Full-Scale Toxin Export Expansion

The stock price of GC Wellbeing is on the rise, fueled by expectations of high growth as the company begins full-scale exports of its global toxin (aesthetic improvement injectable).

As of 9:21 a.m. on September 8, GC Wellbeing was trading at 9,830 won, up 340 won (3.58%) from the previous trading day.

On this day, Hana Securities evaluated GC Wellbeing, stating, "With the full-scale export of global toxin products, a revaluation of the company's valuation (stock price relative to corporate value) is expected."

Choi Jaeho, a researcher at Hana Securities, said, "With the expansion of the high-profit specialty pharmaceuticals and aesthetics segments compared to health functional foods, GC Wellbeing's operating profit margin (OPM) is expected to reach 12.4% this year, up 2.7 percentage points from the same period last year."

In particular, he highlighted the accelerating global expansion of Ininibo, the company's core growth driver in the botulinum toxin segment. Choi noted, "Inivio, acquired last April, possesses a 100% pure toxin strain introduced from Sweden's CCUG, and has the largest domestic GMP (Good Manufacturing Practice) production capacity in a single facility, capable of producing 9 million vials annually."

He added, "Last year, the company signed minimum order quantity (MOQ) contracts worth about $880 million (approximately 1.2 trillion won) with major countries worldwide, and global market entry will proceed sequentially according to each country's regulatory approval schedule. Brazil, which is expected to generate more than 5.8 trillion won in sales, will be the biggest highlight to watch this year."